BAP1 Gene Mutation and Mesothelioma

What Is BAP1?

BAP1 (BRCA1-associated protein 1) is a tumor suppressor gene on chromosome 3p21. It removes ubiquitin tags from target proteins, regulating cell cycle, DNA double-strand break repair, and chromatin remodeling. When BAP1 is lost, cells become more vulnerable to malignant transformation, especially in mesothelial tissue.

The foundational genetic link to mesothelioma was established by Testa JR, Cheung M, Pei J, et al. in Nature Genetics 43(10):1022-1025 in 2011 (DOI 10.1038/ng.912; PMID 21874000). Studying two American families with high mesothelioma incidence and only modest asbestos exposure, Testa and colleagues showed that germline BAP1 loss was the unifying factor, defining what would later be called BAP1 Tumor Predisposition Syndrome (BAP1-TPDS). The same Nature Genetics issue carried a companion paper by Bott M, Brevet M, Taylor BS, et al. (2011) reporting somatic BAP1 mutations in 23% (12/53) of malignant pleural mesotheliomas via candidate-gene sequencing of chromosome 3p21.

BAP1 Tumor Predisposition Syndrome

GeneReviews (Pilarski R, Carbone M, Testa JR, et al., 2020, NCBI Bookshelf NBK390611) catalogs the BAP1-TPDS cancer spectrum:

Cancer type	Lifetime risk in BAP1-TPDS carriers (approx.)	Background population risk
Uveal melanoma	20% to 25%	up to 3%
Cutaneous melanoma	20% to 25%	~2.5%
Mesothelioma (peritoneal-predominant in carriers)	15% to 25%	under 1%
Renal cell carcinoma	up to 20%	~1.6%
Atypical Spitz tumors (BAP1-inactivated melanocytic)	common cutaneous finding, not quantified	rare
Basal cell carcinoma	reported, not quantified	varies
Meningioma, cholangiocarcinoma, others	rare, not quantified	varies

Penetrance figures come from FacingOurRisk’s clinical summary of BAP1-TPDS cohorts and may be inflated by ascertainment bias, since most published cohorts are recruited through hereditary-cancer clinics.

How Common Is BAP1 Loss?

Somatic (tumor) frequency

In sporadic malignant pleural mesothelioma, Bott et al. 2011 found point mutations in 23% (12/53) of tumors. Subsequent next-generation sequencing studies that pair NGS with multiplex ligation-dependent probe amplification (MLPA) detect total BAP1 alterations, including exon-level deletions and copy-number loss, in roughly 50% to 60% of pleural mesothelioma tumors. The commonly cited range is 20% to 25% point mutations and up to 50% to 60% when broader inactivation is included (PMC5504107).

Germline (inherited) frequency

Germline loss-of-function BAP1 variants are rare in the general population. ExAC data summarized in PMID 28062663 put the LoF allele frequency below 0.002. Selected hereditary cohorts show much higher prevalence: roughly 8% of uveal melanoma families harbor germline BAP1 mutations consistent with BAP1-TPDS, per FacingOurRisk’s summary of published cohort data.

How BAP1 Works

The BAP1 protein deubiquitinates target proteins, influencing:

• Cell cycle regulation
• DNA double-strand break repair
• Chromatin remodeling and transcription
• Mitotic spindle stability

When BAP1 is biallelically inactivated (one germline hit plus a somatic second hit, per the classic two-hit model summarized in Carbone M, et al. Carcinogenesis 36(1):76, 2015), mesothelial cells lose this protective machinery and become more susceptible to mineral fiber-driven transformation.

Inheritance pattern

BAP1 mutations follow an autosomal dominant inheritance pattern:

• One mutated copy is sufficient to elevate cancer risk.
• Each first-degree relative of a carrier has a 50% chance of inheriting the variant.
• The mutation passes through families across generations.

BAP1 and Asbestos: Heightened Susceptibility

Asbestos remains the dominant cause of mesothelioma at the population level, but BAP1 carriers appear to develop disease at lower exposure thresholds. In a Carbone-led follow-up cohort summarized by asbestos.com (May 2022), roughly 72% of 79 BAP1 germline carriers with mesothelioma reported no significant occupational asbestos exposure.

In Napolitano et al. (Oncogene 2016), BAP1+/- mice exposed to low-dose asbestos developed mesothelioma at 36% versus 10% in wild-type mice, supporting a gene-environment interaction at fiber doses below typical occupational thresholds.

Survival in BAP1-Germline Mesothelioma

Carbone-cited cohorts (asbestos.com, May 2022) report that BAP1 germline carriers diagnosed with mesothelioma have roughly 7-fold longer median survival, around 5 years, compared with under 1 year median for sporadic mesothelioma. These figures come from selected referral cohorts and have not been replicated in population-based registries, so the magnitude may shrink as data improve.

Patient group	Median survival
Sporadic mesothelioma (Carbone-cited cohorts)	under 1 year
BAP1 germline-carrier mesothelioma (same cohorts)	approximately 5 years

Possible biological reasons under investigation:

• Less aggressive tumor biology in BAP1-loss tumors
• Earlier detection via family-based surveillance
• Higher peritoneal-to-pleural ratio in carriers (peritoneal disease is more often resectable)
• Differential response to chemotherapy and PARP-pathway agents

Other Genes Linked to Mesothelioma

BAP1 is the most frequently implicated germline driver, but not the only one. In Panou et al. (Journal of Clinical Oncology 2018; PMID 30113886), germline mutations in 13 cancer-susceptibility genes were identified in 23 of 198 people with mesothelioma:

Gene	Function
BAP1	Tumor suppressor (most common)
CDKN2A	Cell cycle regulator
BRCA1	DNA repair
BRCA2	DNA repair
PALB2	DNA repair
ATM	DNA damage response
FANCI	DNA repair
FANCC	DNA repair
FANCF	DNA repair
SLX4	DNA repair
PMS1	Mismatch repair
XPC	Nucleotide excision repair
MRE11A	DNA damage sensing

Roughly 12% of mesotheliomas in the Panou 2018 cohort developed in carriers of germline mutations in BAP1 or another cancer-predisposition gene. For broader context on inherited risk, see our mesothelioma genetic testing guide and the BAP1 mechanisms and clinical opportunities review.

Who Should Consider Genetic Testing?

GeneReviews NBK390611 lists features that raise pretest probability of BAP1-TPDS:

• Family history of mesothelioma, especially across multiple relatives
• Multiple primary cancers in one individual or close relatives (uveal melanoma, mesothelioma, RCC, cutaneous melanoma)
• Young-onset mesothelioma
• Uveal melanoma in family history
• Mesothelioma diagnosis with minimal documented asbestos exposure
• Family history of renal cell carcinoma, melanoma, or cholangiocarcinoma

Testing typically uses a blood or saliva sample, is paired with pre-test and post-test genetic counseling, and returns results in roughly 2 to 4 weeks. Detection of a pathogenic variant has implications for first-degree relatives, who can pursue cascade testing.

Surveillance for Known BAP1 Carriers

There is no published comprehensive U.S. NCCN guideline dedicated to BAP1-TPDS surveillance. NCCN renal cancer pathways may reference imaging for known carriers, but no formal BAP1-specific NCCN protocol exists as of this article’s last update. The European Respiratory Society has not published a BAP1-TPDS surveillance guideline either.

The most formal published guidance is the European CanGene-CanVar consensus by Walpole S, Pritchard AL, Cebulla CM, et al. (2023, DOI 10.1002/jmd2.12429; PMID 37607989), built from a Delphi survey of 34 specialists. Headline recommendations:

• Annual full-body dermatologic examination with photography starting in late teens (95% consensus)
• Annual dilated ophthalmologic examination by a clinician experienced in uveal melanoma
• Abdominal MRI every 2 years for renal cell carcinoma screening
• Chest CT annually or every 2 years for mesothelioma surveillance, with frequency at specialist discretion (the panel debated cadence but supported imaging given mesothelioma risk)

Memorial Sloan Kettering’s patient-facing BAP1 guidance recommends early and frequent eye and skin exams plus abdominal MRI for known carriers, without quantified intervals in the patient-education material.

Asbestos Avoidance for Known Carriers

Cascade-tested family members who carry a BAP1 variant should:

• Identify and inventory any asbestos-containing materials in older homes
• Never disturb suspect materials during renovation, demolition, or DIY work
• Avoid occupations and side jobs with known asbestos exposure (insulation, demolition, brake work, shipyard, naval engineering)
• Disclose carrier status to all healthcare providers so imaging surveillance is coordinated

Therapeutic Trials Targeting BAP1 Loss

BAP1 loss creates DNA repair vulnerabilities and chromatin dysregulation that two drug classes have tried to exploit. Both remain investigational; neither has FDA approval for BAP1-mutated mesothelioma.

PARP inhibition: niraparib (NCT03207347 and NERO)

NCT03207347 (UF-ETI-001), a Phase II basket trial of niraparib in BAP1- and DNA damage response-deficient refractory solid tumors, failed its primary efficacy endpoint for overall response per the December 2024 publication (PMID 39626160). Some BAP1-mutated patients had stable disease, but the trial does not support routine niraparib use.

The UK NERO Phase II trial enrolled 84 patients with relapsed mesothelioma (not restricted to BAP1 carriers) and reported a median progression-free survival extension of approximately 1.5 months versus active symptom control, a modest signal that has not changed standard practice.

EZH2 inhibition: tazemetostat (NCT02860286)

NCT02860286 (Trial 16-471) evaluated tazemetostat (Tazverik), an EZH2 inhibitor, in relapsed or refractory BAP1 loss-of-function mesothelioma. The 2022 readout via Dana-Farber reported approximately 50% disease stabilization at 12 weeks among people with pleural mesothelioma. The trial is listed as not currently enrolling in retrieved registry excerpts; tazemetostat is not standard of care for BAP1-mutated mesothelioma.

Questions for Your Doctor

1. Based on my family history and exposure history, am I a candidate for BAP1 germline testing?
2. If my variant is pathogenic, what surveillance schedule will you recommend, and how will you adapt the European CanGene-CanVar 2023 consensus to U.S. care?
3. Should my first-degree relatives pursue cascade testing now?
4. What documented asbestos exposures are on my record, and what avoidance steps make sense going forward?
5. Are any active trials (such as updates from NCT03207347 follow-on studies, or new EZH2-class trials) appropriate for my case?